Who
Michael W. Bonney
Director
Company insider
Files Form 4 as: Director, Autolus Therapeutics; Director, Immunic; Executive Chair, Alnylam Pharmaceuticals; Director, Bristol-Myers Squibb; Executive Chair, Kaleido Biosciences; Director, Dianthus Therapeutics; Director, Sarepta Therapeutics; Director, Celgene Corp /de/.
In numbers
- Trades disclosed
- 325
- Buys
- 10
- Sells
- 22
- Bought
- $2.0M
- Sold
- $42.3M
- Companies
- 16
- Companies where not an officer
- 13
- First trade
- 3 Jan 2006
- Last trade
- 29 Jun 2026
- Last filed
- 1 Jul 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 29 Jun 2026filed 1 Jul 2026 | AUTL Autolus Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —31,667 at $0.00 | filing |
| 29 Jun 2026filed 1 Jul 2026 | AUTL Autolus Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —47,500 at $0.00 | filing |
| 29 Jun 2026filed 1 Jul 2026 | AUTL Autolus Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —31,667 at $0.00 | filing |
| 29 Jun 2026filed 1 Jul 2026 | AUTL Autolus Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —47,500 at $0.00 | filing |
| 29 Jun 2026filed 29 Jun 2026 | IMUX Immunicoption or derivative · Biotechnology | SEC FORM 4 Code A | —100,000 at $0.00 | filing |
| 29 Jun 2026filed 29 Jun 2026 | IMUX Immunicoption or derivative · Biotechnology | SEC FORM 4 Code A | —100,000 at $0.00 | filing |
| 18 Aug 2025filed 19 Aug 2025 | ALNY Alnylam Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —11,250 at $0.00 | filing |
| 18 Aug 2025filed 19 Aug 2025 | ALNY Alnylam PharmaceuticalsBiotechnology | SEC FORM 4 Code M | $790K11,250 at $70.20 | filing |
| 18 Aug 2025filed 19 Aug 2025 | ALNY Alnylam PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $5.1M11,250 at $450.00 | filing |
| 15 May 2025filed 19 May 2025 | ALNY Alnylam Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —11,250 at $0.00 | filing |
| 15 May 2025filed 19 May 2025 | ALNY Alnylam PharmaceuticalsBiotechnology | SEC FORM 4 Code M | $1.5M11,250 at $131.21 | filing |
| 15 May 2025filed 19 May 2025 | ALNY Alnylam PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $147K549 at $267.14 | filing |
| 15 May 2025filed 19 May 2025 | ALNY Alnylam PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $196K729 at $268.56 | filing |
| 15 May 2025filed 19 May 2025 | ALNY Alnylam PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $66K245 at $269.79 | filing |
| 15 May 2025filed 19 May 2025 | ALNY Alnylam PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $117K431 at $271.68 | filing |
| 15 May 2025filed 19 May 2025 | ALNY Alnylam PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $180K660 at $273.16 | filing |
| 15 May 2025filed 19 May 2025 | ALNY Alnylam PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $241K882 at $273.75 | filing |
| 15 May 2025filed 19 May 2025 | ALNY Alnylam PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $83K301 at $275.63 | filing |
| 15 May 2025filed 19 May 2025 | ALNY Alnylam PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $350K1,263 at $277.16 | filing |
| 15 May 2025filed 19 May 2025 | ALNY Alnylam PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $344K1,239 at $278.01 | filing |
News
Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock Gets Price Target Reduction from Wells Fargo & CompanyALNY · tickerreport.com · 17 Oct 2026Bristol Myers Squibb's 4.2% Dividend Yield Comes With a Trade-Off Investors Should KnowBMY · aol.com · 16 Oct 2026Bristol Myers Squibb's Rally Has Momentum, but Can Its New Drugs Justify More Upside?BMY · insidermonkey.com · 16 Oct 2026Head-To-Head Analysis: Milestone Pharmaceuticals (NASDAQ:MIST) & Bristol Myers Squibb (NYSE:BMY)BMY · themarketsdaily.com · 15 Oct 2026Oncocyte (NASDAQ:IMDX) and Alnylam Pharmaceuticals (NASDAQ:ALNY) Critical SurveyALNY · tickerreport.com · 14 Oct 2026Contrasting Sarepta Therapeutics (NASDAQ:SRPT) & AbCellera Biologics (NASDAQ:ABCL)SRPT · tickerreport.com · 11 Oct 2026Head-To-Head Review: Novavax (NASDAQ:NVAX) & Alnylam Pharmaceuticals (NASDAQ:ALNY)ALNY · themarketsdaily.com · 11 Oct 2026
0 headlines in the last 90 days name Michael W. Bonney; 7 articles from the last 14 days about the 6 companies they traded most, at most three about any one of them.